ZLc-002

• Description :

  ZLc-002 is a selective inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain. ZLc-002 can be used for the research of anxiety disorder and inflammation[1][2][3].

• UNSPSC :

  12352211

• Target :

  NO Synthase

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/zlc-002.html

• Solubility :

  10 mM in DMSO

• Smiles :

  COC(CC(N[C@H](C(C)C)C(OC)=O)=O)=O

• Molecular Formula :

  C10H17NO5

• Molecular Weight :

  231.25

• References & Citations :

  [1]Ni HY, et al.Dissociating nNOS (Neuronal NO Synthase) -CAPON (Carboxy-Terminal Postsynaptic Density-95/Discs Large/Zona Occludens-1 Ligand of nNOS) Interaction Promotes Functional Recovery After Stroke via Enhanced Structural Neuroplasticity. Stroke. 2019 Mar;50 (3) :728-737. |[2]Zhu LJ, et al. nNOS-CAPON blockers produce anxiolytic effects by promoting synaptogenesis in chronic stress-induced animal models of anxiety. Br J Pharmacol. 2020 Aug;177 (16) :3674-3690.|[3]Zhu LJ, et al.CAPON-nNOS coupling can serve as a target for developing new anxiolytics. Nat Med. 2014 Sep;20 (9) :1050-4. doi: 10.1038/nm.3644. Epub 2014 Aug 17.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1446971-41-0]